A factory sends a number. A consultant offers a certificate. A distributor says it can “handle FDA.” The launch team feels that the regulatory work has acquired an owner.
But several different jobs may be hiding inside that reassurance: facility registration, product listing, label responsibility, safety records, complaint escalation and communications with a foreign factory. One provider may perform several jobs under a clear arrangement. Buying one does not automatically transfer the others.
The commercial decision is whether the brand has a workable responsibility structure for this product and label, and only then which filings or exemptions apply. Otherwise a team can complete a submission while leaving the most important operating question unanswered.
Follow the label before assigning the work
Under MoCRA, the responsible person is the manufacturer, packer or distributor identified on the product label in the relevant manner. It is not automatically the factory, importer or nearest US company. The statutory registration and listing provisions distinguish facility information from product listing by the responsible person.
For a foreign facility that must register, the US-agent contact belongs to the facility-registration arrangement. FDA's February 2026 facility tutorial identifies that contact separately. A factory's US agent is not, by that appointment alone, the brand's responsible person or customer-support department. Nor does appointing a local distributor automatically settle label responsibility. Check the actual label, entities and agreed scope.
This distinction affects service design as much as paperwork. The entity receiving customer complaints needs a route to the records and people able to assess them. A factory contact who only receives submission reminders is a weak substitute for that route.
A moisturizer launch with an unassigned handoff
Fictional case. Mira Botanics, its moisturizer, partners and documents are invented. The case does not establish that any actual product is a cosmetic, safe, exempt or ready for sale. All proposed claims remain subject to product-specific support and review.
Mira plans a US launch of a 50 ml facial moisturizer made by a Southeast Asian contract manufacturer. Its draft carton names Mira Botanics Pte. Ltd. as distributor. A proposed US reseller wants its own name added. The factory has a US-agent service and says, “We are small, so no MoCRA work is needed.” The brand's support inbox receives inquiries, but nobody has accepted responsibility for escalating product complaints.
The first task is not to submit whatever form is easiest. Mira must settle which label and entity arrangement it intends to use, then have the applicable obligations assessed. Changing the named distributor halfway through preparation can change more than the artwork.
| Workstream | What Mira currently has | Why it does not settle readiness | Decision and next completed output |
|---|---|---|---|
| Label and responsible person | Mira named; reseller addition proposed | Two possible commercial arrangements, no approved final label | Founder: choose proposed arrangement for qualified review; freeze the reviewed label version |
| Factory registration / exemption | Verbal “small business” statement | No documented assessment of the relevant entity, sales basis or excluded products | Factory owner/operator: provide factual basis and obtain a scoped assessment |
| Product listing / exemption | No agreed owner | Factory status does not decide the responsible person's position | Confirmed responsible person: document its own applicable route and maintain the supporting record |
| Safety and complaint response | Technical files at factory; support inbox at brand | Neither proves a usable handoff or complete safety substantiation | Responsible person and product lead: confirm access, review gaps and run a complaint-escalation exercise |
The table deliberately ends with actions, not fictional approval stamps. A reviewer may conclude that a filing is required, an exemption is supported, or the available facts are insufficient. Each result produces a different next task.
“Small” must be assessed; “exempt” must have a scope
FDA's registration and listing guidance describes a small-business sales test using the previous three years' US cosmetic sales and an inflation-adjusted statutory threshold. Headcount and the size of this first order are not substitutes for that test. This article does not calculate a current adjusted dollar threshold or determine Mira's eligibility.
The excluded categories also matter. The exemption does not extend to the relevant facilities or responsible persons for cosmetics that, in customary or usual use, regularly contact the eye's mucous membrane; are injected; are intended for internal use; or are intended to change appearance for longer than 24 hours and are not ordinarily removed by the consumer as part of that use. Both conditions in the last category matter. A loose phrase such as “all long-lasting cosmetics” changes the scope. The current FDA registration page states these boundaries.
Mira should therefore ask for a written, product-and-entity-specific basis, not a replacement “exemption certificate.” FDA states that it does not issue documents certifying registration, listing or exemption, and that assigned numbers do not mean approval. A service provider's branded certificate is not evidence of FDA approval.
There are three legitimate working states. Required: assign and complete the applicable submissions and ongoing work. Exemption supported: preserve the factual basis and identify the duties still applicable. Unknown: obtain the missing sales, product-use or entity information before treating the exemption as established. Unknown is not a cheaper version of exempt.
An exemption cannot answer a safety complaint
FDA's MoCRA overview addresses safety substantiation and serious-adverse-event reporting as separate obligations. The statutory reporting clock gives the responsible person 15 business days after receiving the serious-adverse-event report to submit it. A registration/listing exemption is not a blanket release from the rest of the law.
For Mira, the useful rehearsal is operational: a customer says the product caused an injury and sends a lot photograph. Can support preserve the original account, connect the lot to the product record, and reach the designated qualified assessor promptly? Who decides whether the event is reportable, who submits when required, and who follows up? The exercise should reveal an unowned handoff before a real complaint does. It is not a script for a support agent to make a medical assessment.
An arrangement that merely forwards emails without an accepted owner, backup and access to records has not solved that problem. The brand may outsource submission work, but the role map must still identify who remains accountable for the underlying obligation.
A finished launch decision, and more honest customer copy
Mira's internal decision can read:
Decision for the 50 ml US moisturizer launch: do not print the proposed carton or open sales yet. Freeze the intended label/entity arrangement for review. Obtain separate documented conclusions on the factory's registration position and the responsible person's listing position, including any claimed exemption basis. Confirm safety-record access and close identified gaps. Name the complaint escalation owner and backup, and complete the lot-to-assessor exercise before launch authorization. The US-agent contract remains a facility service; it does not substitute for these decisions.
The rejected promotional line is: “FDA-approved moisturizer, certified under MoCRA.” A restrained draft, limited to the supplied product identity, is: “Mira facial moisturizer, 50 ml. For external cosmetic use. Product questions or concerns: contact Mira support through the contact details on the pack.” This is an example of removing an unsupported approval claim, not a complete or approved US label. Required warnings, directions, ingredient information and contact labeling must be reviewed for the actual product.
The recommendation could change quickly if the final label, role acceptance and product evidence already exist and the only gap is a correctly scoped submission. Conversely, stronger marketing demand cannot repair an unassigned safety obligation. The founder's next spend should buy the missing decision and operating capability, rather than another document that only looks reassuring.